{
  "abstract": "Background Bacterial sexually transmitted infections (STIs), particularly Chlamydia trachomatis and Neisseria gonorrhoeae, remain highly prevalent among individuals using HIV pharmacologic prevention strategies. The PrIDE Cohort provides data to evaluate STI burden over time in a large real-world population of PrEP-users engaged in structured follow-up. We assessed prevalence and short-term trends of chlamydia and gonorrhea in this cohort.Methods We analyzed data from 1,959 participants enrolled in the PrIDE Cohort. Baseline demographic and behavioral characteristics were collected at enrollment (T0). Participants underwent screening for chlamydia and gonorrhea at baseline and follow-up visits at 3 (T1), 6 (T2), and 9 months (T3). Prevalence was calculated as the proportion of positive tests among those screened at each visit, with 95% confidence intervals (CI).Results At baseline, median age was 38 years (IQR 32–46); 98.4% were assigned male sex at birth and 97.1% identified as cisgender. A high proportion reported behavioral risk factors, including ≥6 sexual partners in the prior 3 months (60.8% among those reporting) and 10.7% reporting chemsex. Doxycycline post-exposure prophylaxis use was reported by 9.1% at T0, 6.1% at T1 and 7.9% at T2.At T0, overall prevalence of chlamydia or gonorrhea was 15.1% (296/1,959; 95% CI 13.6–16.8). Chlamydia prevalence was 8.5% (166/1,959; 95% CI 7.3–9.8) and gonorrhea prevalence was 9.1% (179/1,959; 95% CI 7.9–10.5).At 3 months (n=699 screened), overall STI prevalence was 13.7% (95% CI 11.3–16.5); chlamydia 7.2% (50/699; 95% CI 5.4–9.3) and gonorrhea 7.7% (54/699; 95% CI 5.9–10.0).At 6 months (n=328 screened), overall STI prevalence was 15.2% (95% CI 11.5–19.6); chlamydia 7.3% (24/328; 95% CI 4.7–10.7) and gonorrhea 9.8% (32/328; 95% CI 6.8–13.5).No significant differences in prevalence were observed across follow-up visits compared with baseline [figure 1].Conclusions In this large prospective PrEP cohort, bacterial STI prevalence was high at initiation and remained stable over six months of follow-up, with no evidence of an increasing trend despite regular scheduled screening. These findings suggest that PrEP programs primarily engage individuals already at elevated risk, rather than driving short-term increases in STI burden. The absence of a rising trend under systematic testing does not support a detection-driven escalation of STI prevalence in the early follow-up period.Abstract P210 Figure 1Temporal trends of STIs over time",
  "authors": [
    {
      "affiliations": [
        "Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy"
      ],
      "name": "D Moschese"
    },
    {
      "affiliations": [
        "Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy"
      ],
      "name": "L Oreni"
    },
    {
      "affiliations": [
        "Fondazione ICONA, Milan, Italy"
      ],
      "name": "G Frate"
    },
    {
      "affiliations": [
        "National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy"
      ],
      "name": "R Esvan"
    },
    {
      "affiliations": [
        "ASST Santi Paolo e Carlo, Milan, Italy"
      ],
      "name": "A De Bona"
    },
    {
      "affiliations": [
        "ASL Città di Torino, Turin, Italy"
      ],
      "name": "AM Lucchini"
    },
    {
      "affiliations": [
        "Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy"
      ],
      "name": "S Lazzarin"
    },
    {
      "affiliations": [
        "Padua University Hospital, Padua, Italy"
      ],
      "name": "AM Cattelan"
    },
    {
      "affiliations": [
        "Roma Check Point, Rome, Italy"
      ],
      "name": "VL del Negro"
    },
    {
      "affiliations": [
        "PLUS aps (BLQ Checkpoint), Bologna, Italy"
      ],
      "name": "S Cerere"
    },
    {
      "affiliations": [
        "Circolo di Cultura Omosessuale Mario Mieli, Rome, Italy"
      ],
      "name": "M Marra"
    },
    {
      "affiliations": [
        "ASST Papa Giovanni XXIII, Bergamo, Italy"
      ],
      "name": "S Venturelli"
    },
    {
      "affiliations": [
        "Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy"
      ],
      "name": "M Menozzi"
    },
    {
      "affiliations": [
        "National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy"
      ],
      "name": "RJ Steiner"
    },
    {
      "affiliations": [
        "ASL Città di Torino, Turin, Italy"
      ],
      "name": "M Tutone"
    },
    {
      "affiliations": [
        "ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"
      ],
      "name": "R Rossotti"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy"
      ],
      "name": "S Nozza"
    },
    {
      "affiliations": [
        "ASA Milano, Milan, Italy"
      ],
      "name": "M Cernuschi"
    },
    {
      "affiliations": [
        "National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy"
      ],
      "name": "V Mazzotta"
    }
  ],
  "title": "P210 No evidence of rising STI prevalence during early PrEP follow-up in the Italian PrIDE cohort",
  "uid": "fec1b0cb-34a3-538c-a610-84fda75a8998"
}